TRPV1 has also been proposed as a negative prognosis marker for glioblastoma (Nabissi et al., 2016), in which invasiveness is highly dependent on RhoA activity since it regulates several matrix metalloproteinases in this type of neoplasms (Al-Koussa et al., 2020). This evidence concerns the gene RHOA and glioblastoma.